Qualigen Therapeutics, Inc.

NasdaqCM QLGN

Qualigen Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 2.98 M

Qualigen Therapeutics, Inc. Market Capitalization is USD 2.98 M on January 14, 2025, a 1,064.76% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Qualigen Therapeutics, Inc. 52-week high Market Capitalization is USD 3.75 M on November 05, 2024, which is 25.72% above the current Market Capitalization.
Qualigen Therapeutics, Inc. 52-week low Market Capitalization is USD 72.78 K on October 31, 2024, which is -97.56% below the current Market Capitalization.
Qualigen Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 751.43 K.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: QLGN

Qualigen Therapeutics, Inc.

CEO	Mr. Kevin A. Richardson II
IPO Date	June 23, 2015
Location	United States
Headquarters	2042 Corte Del Nogal
Employees	4
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key trends

Past 5 years